

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

## Complete if Known

Application Number	10/642,272
Filing Date	August 18, 2003
First Named Inventor	Fumiyuki HATTORI
Group Art Unit	To Be Assigned 1632
Examiner Name	To Be Assigned Marcia Noble
Attorney Docket Number	58777.000012

## U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	U1					
	U2					

## FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
MN	/	EP	503582 A1		Senju Pharmaceutical	09-16-1992	✓	
MN	/	EP	515995 A2		Poli Industria Chimica S.p.A.	12-02-1992	✓	
MN	/	EP	768314 A1		Senju Pharmaceutical	04-16-1997	✓	
	/	EP	067267 A1		ADIR	12-23-1993	✓	
	/	WO	95/04041 A1		Taisho Pharmaceutical	02-09-1995	✓	
MN	/	WO	99/53917 A1		United States Government	10-28-1999	✓	
MN	/	WO	00/55174 A1		Human Genome Sciences	09-21-2000	✓	

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MN	P1	BRYK, R. et al., "Peroxynitrite reductase activity of bacterial peroxiredoxins", <i>Nature</i> (2000), Vol. 407, No. 6801, pp. 211-215	✓
MN	P2	MATSUMOTO, Akio et al., "Cloning of the peroxiredoxin gene family in rats and characterization of the fourth member", <i>FEBS Letters</i> (1999), Vol. 443, No. 3, pp. 246-250	✓
MN	P3	NEMOTO, Y. et al., "Antisense RNA of the latent period gene (MER5) inhibits the differentiation of murine erythroleukemia cells", <i>Gene</i> (1990), Vol. 91, No. 2, pp. 261-265	✓
	P4	TATEWAKI, Masuo, "Ketsueki Kansaiho no Zoshoku to Bunka" <i>Chem. Abstr.</i> (1992), Vol. 117 (Columbus, OH)	

Examiner Signature

/Marcia Noble/

Date Considered

07/18/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

## **Complete if Known**

Application Number	10/642,272
Filing Date	August 18, 2003
First Named Inventor	Fumiyuki HATTORI
Group Art Unit	To Be Assigned 1632
Examiner Name	To Be Assigned Marcia Noble
Attorney Docket Number	58777.000012

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	P5	<del>TATEWAKI, Masuo, Sekkekkyu Bunka no Yudo", Chem Abstr (1995), Vol. 122, (Columbus, OH)</del>	
MN	P6	TSUJI, K. et al., "Mammalian antioxidant protein complements alkylhydroperoxide reductase (ahpC) mutation in Escherichia coli., Biochem. J. (1995), Vol. 307, No. Pt. 2, pp. 377-81	✓
MN	P7	WATABE, S. et al., "Purification and characterization of a substrate protein for mitochondrial ATP-dependent protease in bovine adrenal cortex", J. Biochem. (1994), Vol. 115, No. 4, pp. 648-654	✓
MN	P8	YAMAMOTO, T. et al., "Cloning of a housekeeping-type gene (MER5) preferentially expressed in murine erythroleukemia cells", Gene (1989), Vol. 80, No. 2, pp. 337-343	✓

Examiner Signature	Marcia S. Noble <small>I solemnly swear that I am Marcia S. Noble, U.S. Patent and Trademark Office, and I am not a person who is prohibited from practicing before the U.S. Patent and Trademark Office.</small>	/Marcia Noble/	Date Considered	07/18/2006
--------------------	--	----------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
)  
Fumiyuki HATTORI et al. ) Group Art Unit: ~~To Be Assigned~~ 1632  
)  
Application Number: 10/642,272 ) Examiner: ~~To Be Assigned~~ Marcia Noble  
)  
Filed: August 18, 2003 )  
)  
For: THERAPEUTIC METHODS AND AGENTS FOR DISEASES ASSOCIATED WITH  
DECREASED EXPRESSION OF AOP-1 GENE OR AOP-1

INFORMATION DISCLOSURE STATEMENT**Mail Stop Patent Application**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

In accordance with 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicant respectfully requests consideration of the references listed on the attached Form PTO/SB/08A. Copies of the references listed are also enclosed, except for items P4, TATEWAKI, Masuo, "Ketsueki Kansaiibo no Zoshoku to Bunka", *Chem. Abstr.* (1992), Vol. 117, (Columbus, OH), and P5, TATEWAKI, Masuo, "Sekkekkyu Bunka no Yudo", *Chem. Abstr.* (1995), Vol. 122, (Columbus, OH). Applicants will submit copies of the references when they are obtained.


Applicant respectfully requests that the Examiner consider the references cited on the Form PTO/SB/08A and that the Examiner indicate that the references have been considered in this application by returning a copy of the Form PTO/SB/08A with the Examiner's initials in the left column per MPEP 609.

Applicants' submission of this Information Disclosure Statement (IDS) shall not be construed as an admission that the cited references are prior art to the present invention, or that the cited references qualify as printed publications. The submission of this IDS also shall not be construed as a representation that a prior art search has been performed.

This IDS is submitted prior to the issuance of a first Office Action on the merits; therefore, it is believed that no fees are required in connection therewith. If any fees are necessitated by the filing of this Information Disclosure Statement, please charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

Date: 4 Dec 2003

By:   
Robert M. Schulman  
Registration No. 31,186

Jeffrey T. Perez  
Registration No. 52,110

HUNTON & WILLIAMS LLP  
1900 K Street, N.W., Suite 1200  
Washington, DC 20006-1109  
(202) 955-1500 (telephone)  
(202) 778-2201 (facsimile)

RMS/JTP/cbt